Charles Schwab Investment Management Inc Allogene Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,178,848 shares of ALLO stock, worth $2.56 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,178,848
Previous 1,178,401
0.04%
Holding current value
$2.56 Million
Previous $2.75 Million
20.22%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding ALLO
# of Institutions
163Shares Held
134MCall Options Held
59.4KPut Options Held
113K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$40.6 Million1.25% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$35.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$18.1 Million0.0% of portfolio
-
State Street Corp Boston, MA7.01MShares$15.2 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$15 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $312M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...